A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study
Plain-language summary
This trial is testing Golidocitinib for patients with various types of peripheral T-cell lymphoma (PTCL) who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Researchers want to learn whether this approach can help control the lymphoma. This trial is available at 1 location in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years or older
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Golidocitinib (DRUG): 150 mg once per day by PO | Cyclophosphamide (DRUG): 750 mg/m2 by IV | Doxorubicin (DRUG): 50 mg/m2 by IV | Vincristine (DRUG): 1.4 mg/m2 (max: 2 mg) by IV | Prednisone (DRUG): 100 mg by PO
Golidocitinib, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details